Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2010

View Archived Issues

Clinical data presented on rituximab in ANCA-associated vasculitis and SLE

Agennix discloses interim data from first-in-human trial of RGB-286638 in hematologic tumors

Chugai Pharma presents in vivo data on new potential cancer therapeutics

Thioketal nanoparticles deliver siRNA against TNF-alpha to inflamed intestines in colitis model

Elorac's naloxone lotion receives FDA orphan drug status in CTCL-associated pruritus

Neuraltus reports topline phase I data on NP-001 in ALS

Enrollment complete in phase III edoxaban trial for stroke prevention in AF

Hana Biosciences becomes Talon Therapeutics

Phase IIb trial of PT-003 in COPD meets primary efficacy endpoint

AstraZeneca identifies novel dipeptidyl peptidase 1 inhibitors

Spanish scientists patent new bivalent pyrazole derivatives

Novartis claims new inhibitors of sodium/glucose cotransporters

CardioVascular BioTherapeutics licenses phase II data for FGF-1

FDA approves Octaplex IND and grants fast track status

Scientists use [18F]-FDG PET-CT scan for early detection of cancer in subjects with LFS

GenSpera adds trial site to G-202 phase I clinical program

AMT and Amgen amend licencing agreement for GDNF gene therapies

Tolerx and the Cancer Research Institute partner for TRX-518

FDA provides complete response letter to GSK and Valeant for ezogabine

Shire reports efficacy and safety results from FAST-3 study of icatibant

Ascenta Therapeutics and Ascentage Pharma form alliance for cancer programs

Argos doses patients in phase IIb Arcelis personalized HIV immunotherapy trial

Michael J. Fox Foundation awards Allon grant for Parkinson's disease research

Gradient Echo Plural Contrast Imaging monitors progression of MS

TAvi6, a bispecific antibody targeting VEGF-A/ANG-2 inhibits angiogenesis in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...